Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung.

Autor: Kang TM; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Hardcastle N; Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum, Department of Oncology, University of Melbourne, Australia; Centre for Medical Radiation Physics, University of Wollongong, New South Wales, Australia., Singh AK; Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Slotman BJ; Department of Radiation Oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands., Videtic GMM; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA., Stephans KL; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA., Couñago F; Department of Radiation Oncology, Hospital Universitario Quirónsalud, Madrid, Spain., Louie AV; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Guckenberger M; Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Harden SV; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Plumridge NM; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Siva S; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum, Department of Oncology, University of Melbourne, Australia. Electronic address: shankar.siva@petermac.org.
Jazyk: angličtina
Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Aug; Vol. 170, pp. 185-193. Date of Electronic Publication: 2022 Jun 30.
DOI: 10.1016/j.lungcan.2022.06.014
Abstrakt: Stereotactic ablative radiotherapy (SABR) is a well-established treatment for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and pulmonary oligometastases. The use of single-fraction SABR in this setting is supported by excellent local control and safety profiles which appear equivalent to multi-fraction SABR based on the available data. The resource efficiency and reduction in hospital outpatient visits associated with single-fraction SABR have been particularly advantageous during the COVID-19 pandemic. Despite the increased interest, single-fraction SABR in subgroups of patients remains controversial, including those with centrally located tumours, synchronous targets, proximity to dose-limiting organs at risk, and concomitant severe respiratory illness. This review provides an overview of the published randomised evidence evaluating single-fraction SABR in primary lung cancer and pulmonary oligometastases, the common clinical challenges faced, immunogenic effect of SABR, as well as technical and cost-utility considerations.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: